Elan appoints Ingram as new chair; Cubist files citizen petition;

@FiercePharma: Sanofi sales reps call in for layoff news. Article | Follow @FiercePharma 

> Irish biotech group Elan has appointed former Glaxo Wellcome chief executive Robert Ingram as its new chairman. Ingram will take up the role on January 26th, taking over from Kyran McLaughlin, who announced in April that he intended to step down once a  successor had been found. News

> Cubist Pharmaceuticals (NASDAQ: CBST) today announced that the company has filed a citizen petition with the FDA, urging the agency to refrain from approving any ANDA for generic daptomycin until certain conditions are satisfied. Cubist release

> AstraZeneca's anti-clot drug Brilique, a rival to the world's second-best-selling medicine, Plavix, won European Union approval for use in patients with diseases of the coronary arteries that feed the heart. Story

> Roche Holding AG's MabThera medicine helped keep a common form of blood cancer at bay without the need for additional therapy, a study found. Item

> Indian drugmaker Glenmark Pharmaceuticals and U.S. partner Lehigh Valley Technologies said Monday the FDA has approved two new-drug applications that will allow the companies to manufacture and sell a line of products containing painkiller oxycodone hydrochloride. Article

> India's largest drug maker by value Sun Pharmaceutical Industries Ltd said on Saturday that is planning to delist its U.S.-based subsidiary Caraco Pharmaceutical Laboratories by acquiring the remaining 24 percent stake in that company for $4.75 a share. News

> Five men put the health of sick patients at risk in the most serious fake medicine scam ever seen in the European Union, a court heard today. Motivated by greed, the British businessmen were involved in an operation to import counterfeit prescription drugs for conditions including prostate cancer, heart disease and schizophrenia, from China to the UK, and pretend they were genuine products, to sell them, Croydon Crown Court was told. Item

Biotech News

 @FierceBiotech: As overseas trials boom, questions about safety arise. Article | Follow @FierceBiotech

> Seattle Genetics ($SGEN) unveils pivotal cancer data, plans for FDA app. News

> Kindler's reign at Pfizer beset by R&D failures. Article 

> AZ survey taps China as world's most innovative country in 2020. Report 

Biotech IT News

> Roche, AZ find little of use in data flood. Report 

> Look beyond compliance for ROI on IT. Story

> AMA: Docs must police each other in social media. News 

> Big-data attack targets schizophrenia. Article 

> Data deal supports fast-track case. News 

> ScenPro to convert FDA cross-center clinical data for comparisons. Story 

And Finally... A Melbourne snakebite antivenom supplier has been listed by the U.S. as critical strategic infrastructure in a diplomatic cable published by WikiLeaks. The Melbourne-based pharmaceutical group Mayne Pharma is the only producer of the Crotalidae Polyvalent Immune Fab snake antivenom. Known as CroFab, the antivenom works against bites from rattlesnakes, copperheads and other U.S. snakes. Also, Danish companies such as Novo Nordisk and Bavarian Nordic are potential terror targets, according to confidential documents released by WikiLeaks. Story | News

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.